March 2025 Quarterly Activities Report and Appendix 4C

Emyria Limited (ASX: EMD) continues to strengthen its position as a leader in innovative mental health care, with key milestones achieved this quarter.

Highlights include strong clinical outcomes from Emyria’s unique PTSD treatment program, the launch of a new therapy program for treatment-resistant depression, progress towards first funded pilot programs with health insurers, a leadership restructure to drive growth and innovation, and the expansion of clinical capacity with the opening of a second Empax Centre.

These achievements support Emyria’s mission to expand access to advanced mental health treatments and build sustainable revenue streams.